Ventyx Bio Cardiovascular Drug’s Phase 2 Results Set Up Talks With a Big Pharma Firm
An experimental Ventyx Biosciences drug led to statistically significant reductions in blood levels of a protein that’s an indicator of cardiovascular risk, preliminary Phase 2 results that support this molecule’s approach of addressing what is becoming a competitive inflammation target for heart disease. The data readout also starts the clock on negotiations with a big…